For laboratory research use only — not for human or veterinary use. Not evaluated by the U.S. FDA.
Secretagogue Peptide
Tesamorelin
A 44-amino-acid GHRH analog studied in clinical research on growth-hormone secretion and visceral adipose tissue.
Size
Quantity
$67.99
Bundle & save
Delivery
Order by 3:00 PM ET for same-day dispatch
Cutoff 3:00 PM ET · same-day dispatch
Estimated arrival in 2–3 business days
Overnight shipping available
Free shipment protection included
Tesamorelin
1 × 10mg · $67.99
99% purity, QC passed
HPLC + mass-spec verified
Shipment protection
Free on every order
Free shipping over $150
Same-day dispatch before 3PM ET
Certificate of Analysis
Third-party tested · Independent analytical lab
10mg
98.76%latest
| Tested | Measured | Purity |
|---|---|---|
| Jul 2026 | 11.12mg | 98.76% |
| Jul 2026 | 11.56mg | 99.17% |
| Jul 2026 | 11.62mg | 98.88% |
| Jun 2026 | 11.32mg | 98.08% |
| Jun 2026 | 11.65mg | 99.01% |
| May 2026 | 12.06mg | 98.72% |
| May 2026 | 11.80mg | 99.02% |
| May 2026 | 11.89mg | 99.00% |
| May 2026 | 11.72mg | 99.34% |
| Apr 2026 | 11.60mg | 99.68% |
20mg
99.36%latest
| Tested | Measured | Purity |
|---|---|---|
| Jul 2026Sterile | 23.57mg | 99.36% |
| Jun 2026 | 20.99mg | 99.19% |
| Jun 2026 | 22.01mg | 98.55% |
| May 2026 | 22.21mg | 99.01% |
| May 2026 | 22.53mg | 99.47% |
| Apr 2026 | 21.81mg | 99.51% |
| Apr 2026 | 23.30mg | 99.85% |
| Apr 2026 | 22.40mg | 99.65% |
| Feb 2026 | 23.57mg | 99.33% |
| Jan 2026 | 21.84mg | 99.71% |
Latest safety testing
- Sterility
- TAMC/TYMCJul 2026
Endotoxin, sterility, and heavy-metals reports are run on individual lots on a rotating basis, separate from the identity/purity assay above — not on every lot.
Frequently researched together
Commonly studied alongside Tesamorelin.
Compound information
Technical specifications
Storage & stability
- ❄️
Lyophilized (powder)
-20°C · stable 2+ years
- ❄️
Reconstituted
2–8°C · use within 30 days
Sources & references
Peer-reviewed literature, for research context
- Journal of Clinical Endocrinology & Metabolism
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data
2010·PMID: 20554713Falutz J, et al.
View source - Lancet HIV
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial
2019·PMID: 31611038Stanley TL, et al.
View source - Archives of Neurology
Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial
2012·PMID: 22869065Baker LD, et al.
View source - Journal of Frailty & Aging
The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV
2019·PMID: 31237318Adrian S, et al.
View source - JCI Insight
Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD
2020·PMID: 32701508Fourman LT, et al.
View source
Important research notice
Not for human consumption. This product is sold exclusively for laboratory and in vitro research. It is not intended to diagnose, treat, cure, or prevent any disease.
Any research findings referenced on this page are drawn from published, peer-reviewed literature and are provided for educational context only. They are not product claims and should not be read as medical advice.
By purchasing, you confirm you are a qualified researcher and will handle this material in accordance with all applicable laws and institutional guidelines.